Several LAG-3–targeting molecules are currently in early stages of clinical development with early results suggesting a modest benefit when used as single agents, but dual LAG-3/PD-1 blockade has a significant role in reducing tumour growth by increasing the proportion of effector T cells in the tumour [154, 155]. Here, LAG3 is linked to neoplasm.